Activity Overview
This activity is designed to help pathologists and laboratory professionals learn how PD-L1 testing and interpretation is performed in patients with advanced triple negative breast cancer (TNBC). Panelists will also discuss key considerations when assessing pathological complete response (pCR) following neoadjuvant therapy.
Provided by the American Society for Clinical Pathology in partnership with Q Synthesis LLC.
Target Audience
This activity has been designed to meet the educational needs of pathologists and laboratory professionals diagnosing cancer.
Activity Agenda
· Introductions
· Review when and how PD-L1 testing is performed in TNBC
· Panel discussion: considerations when assessing pathological response following neoadjuvant therapy
· Summary of key takeaways
Learning Objectives
Upon completion of this activity, you will be able to:
· Describe the role of PD-L1 testing in triple-negative breast cancer (TNBC).
· Discuss recent advances in neoadjuvant immunotherapy for patients with TNBC.
· Summarize how pathological response is assessed in patients with breast cancer who receive neoadjuvant therapy.
Faculty
|
Marilin Rosa, MD |
Senior Member, Moffitt Cancer Center and Research Institute
Professor, University of South Florida
Tampa, Florida
Section Head of Breast Pathology
Director of the Breast Pathology Fellowship at Moffitt |
|
Huina Zhang, MD, PhD |
Associate Professor - Department of Pathology and Laboratory Medicine (SMD)
University of Rochester Medical Center
Rochester, NY |
|
Lamees Saeed, MD |
Breast and Molecular Pathology Fellow at Moffitt Cancer Center |
|
Joseph Kim, MD |
President of Q Synthesis LLC |
Faculty Disclosures
All relevant financial relationships for Marlin Rosa have been mitigated.
Huina Zhang, Lamees Saeed, and Joseph Kim have no relevant financial relationships to disclose.
Accreditation Statement
The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.
Credit Designation Statement
The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.
The ASCP designates this activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)â„¢. Physicians should claim only credit commensurate with the extent of their participation in the activity.
ASCP designates this activity for a maximum of 0.5 CMLE credit. This activity meets CMP and state re-licensure requirements for laboratory personnel.
For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, during normal business hours: Monday through Friday, 8 a.m. to 6 p.m. Eastern Time.
Method of Participation
To complete the activity and receive credit, the participant must complete the online activity. CME certificates will be provided online.
Commercial Support
This activity is funded by an independent educational grant from Merck.